Roche tumbles after Avastin disappoints in Phase III adjuvant colon cancer trial
This article was originally published in Scrip
Executive Summary
Roche's best-selling cancer drug Avastin has failed to meet its primary goal of preventing disease recurrence (improving disease-free survival) in colon cancer patients whose tumours had been removed through surgery in its first Phase III trial, NSABP C-08, in the adjuvant setting, which was sponsored by the US National Cancer Institute (NCI).